99% Purity Peptide Powder Bivalirudin CAS: 128270-60-0 for Angina Pectoris

99% Purity Peptide Powder Bivalirudin CAS: 128270-60-0 for Angina pectoris

Quick Details of Bivalirudin:
 



Bivalirudin  Descriptions:

Bivalirudin (Angiomax or Angiox, manufactured by The Medicines Company) is a specific and reversible direct thrombin inhibitor (DTI).
Chemically, it is a synthetic congener of the naturally occurring drug hirudin (found in the saliva of the medicinal leech Hirudo medicinalis).
Bivalirudin is a DTI that overcomes many limitations seen with indirect thrombin inhibitors, such as heparin. Bivalirudin is a short, synthetic peptide that is potent, highly specific, and a reversible inhibitor of thrombin. It inhibits both circulating and clot-bound thrombin, while also inhibiting thrombin-mediated platelet activation and aggregation. Bivalirudin has a quick onset of action and a short half-life. It does not bind to plasma proteins (other than thrombin) or to red blood cells. Therefore, it has a predictable antithrombotic response. There is no risk for Heparin Induced Thrombocytopenia/Heparin Induced Thrombosis-Thrombocytopenia Syndrome (HIT/HITTS). It does not require a binding cofactor such as antithrombin and does not activate platelets. These characteristics make bivalirudin an ideal alternative to heparin.
Bivalirudin clinical studies demonstrated consistent positive outcomes in patients with stable angina, unstable angina (UA), non-ST segment elevation myocardial infarction (NSTEMI), and ST-segment elevation myocardial infarction (STEMI) undergoing PCI in 7 major randomized trials. Patients receiving bivalirudin had fewer adverse events compared to patients that received heparin.

Bivalirudin  Applications:

Regardless of whether it is thrombin in the blood circulation or thrombin combined with thrombus, bivalirudin can specifically bind to its catalytic site and anion binding site, thereby directly inhibiting the activity of thrombin, and its characteristic is short-lived. ,reversible. Early clinical studies have shown that bivalirudin has a definite anticoagulant effect and has a lower incidence of bleeding events and is safer than traditional heparin anticoagulant therapy. It is mainly used to prevent angioplasty interventional treatment of ischemic complications of unstable angina.
In vitro, this product has both inhibitory effects on both soluble and thrombin-bound thrombin. This effect is not affected by the product of platelet release, and prolongs plasma activated partial thromboplastin time, coagulation in a dose-dependent manner. Enzyme time and prothrombin time. Suitable for percutaneous coronary intervention (PCI) for unstable angina.

Our order process:
Our competitive advantages: 99% Purity Peptide Powder Bivalirudin CAS: 128270-60-0 for Angina pectoris

Quick Details of Bivalirudin:
 



Bivalirudin  Descriptions:

Bivalirudin (Angiomax or Angiox, manufactured by The Medicines Company) is a specific and reversible direct thrombin inhibitor (DTI).
Chemically, it is a synthetic congener of the naturally occurring drug hirudin (found in the saliva of the medicinal leech Hirudo medicinalis).
Bivalirudin is a DTI that overcomes many limitations seen with indirect thrombin inhibitors, such as heparin. Bivalirudin is a short, synthetic peptide that is potent, highly specific, and a reversible inhibitor of thrombin. It inhibits both circulating and clot-bound thrombin, while also inhibiting thrombin-mediated platelet activation and aggregation. Bivalirudin has a quick onset of action and a short half-life. It does not bind to plasma proteins (other than thrombin) or to red blood cells. Therefore, it has a predictable antithrombotic response. There is no risk for Heparin Induced Thrombocytopenia/Heparin Induced Thrombosis-Thrombocytopenia Syndrome (HIT/HITTS). It does not require a binding cofactor such as antithrombin and does not activate platelets. These characteristics make bivalirudin an ideal alternative to heparin.
Bivalirudin clinical studies demonstrated consistent positive outcomes in patients with stable angina, unstable angina (UA), non-ST segment elevation myocardial infarction (NSTEMI), and ST-segment elevation myocardial infarction (STEMI) undergoing PCI in 7 major randomized trials. Patients receiving bivalirudin had fewer adverse events compared to patients that received heparin.

Bivalirudin  Applications:

Regardless of whether it is thrombin in the blood circulation or thrombin combined with thrombus, bivalirudin can specifically bind to its catalytic site and anion binding site, thereby directly inhibiting the activity of thrombin, and its characteristic is short-lived. ,reversible. Early clinical studies have shown that bivalirudin has a definite anticoagulant effect and has a lower incidence of bleeding events and is safer than traditional heparin anticoagulant therapy. It is mainly used to prevent angioplasty interventional treatment of ischemic complications of unstable angina.
In vitro, this product has both inhibitory effects on both soluble and thrombin-bound thrombin. This effect is not affected by the product of platelet release, and prolongs plasma activated partial thromboplastin time, coagulation in a dose-dependent manner. Enzyme time and prothrombin time. Suitable for percutaneous coronary intervention (PCI) for unstable angina.

Our order process:
Our competitive advantages:

FFP2 Mask

Best Reusable Ffp2 Mask Uk,Reusable Ffp2 Mask Uk,Ffp2 Mask Vs N95,Ffp2 Mask Vs Kn95

Zhejiang Lanhine Medical Products Ltd. , https://www.lanheyiliao.com